The Effect of Inflammatory Markers on Survival in Advanced Biliary Tract Carcinoma Treated with Gemcitabine/Oxaliplatin Regimen

Büyükşimşek, Mahmut; Kidi, Mehmet Mutlu; Oğul, Ali; Mirili, Cem; Paydaş, Semra

doi:10.1007/s12029-020-00396-x

Cited by 7 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparisons with previous studies may be difficult because of their different populations and stages. Patients with an elevated NLR experience shorter survival 1,33–35 . However, we show a significant association between LCR and PFS.…”

Section: Discussionmentioning

confidence: 45%

“…[17][18][19][20] In CCA, an elevated NLR immediately before surgery or chemotherapy potentially predicts shorter PFS and OS. 1,[32][33][34][35] In EHCC, the NLR is not significantly associated with PFS, CSS, or OS, although an elevated PLR is significantly associated with shorter PFS and OS. 36 Here, when we analyzed the data immediately before RT, but not before initial treatment, the NLR and PLR were not significantly associated with treatment outcomes.…”

Section: Discussionmentioning

confidence: 97%

“…Most studies report that an elevated NLR before initial surgery, chemotherapy, or RT, or combined, is associated with poor prognoses of patients with lung cancer, uterine cervical cancer, ovarian cancer, and many other solid tumors 17–20 . In CCA, an elevated NLR immediately before surgery or chemotherapy potentially predicts shorter PFS and OS 1,32–35 . In EHCC, the NLR is not significantly associated with PFS, CSS, or OS, although an elevated PLR is significantly associated with shorter PFS and OS 36 .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic markers including immune and inflammatory factors predict outcomes in patients receiving postoperative radiation therapy for cholangiocarcinoma

Mukai

Matsuyama

Sugiura

et al. 2022

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Purpose: This study aimed to analyze treatment outcomes and prognostic markers, including immune and inflammatory factors, of postoperative radiation therapy (RT) administered to patients with cholangiocarcinoma (CCA). Methods:We retrospectively included 59 patients with CCA who underwent surgery and postoperative RT with curative intent from 2004 to 2019. Patients received external irradiation (50 Gy in 25 fractions) using three-dimensional RT. We analyzed prognostic factors of inflammation, such as pre-RT platelet count, hemoglobin, lymphocyte count ratio (LCR) of the leukocyte count, platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR).Results: Tumor stages were distributed as follows: I (n = 8), II (n = 25), III (n = 15), and IVA (n = 11). The median follow-up was 24 months. Two-year overall survival (OS), cause-specific survival (CSS), progression-free survival (PFS), and locoregional control (LRC) rates were 59.5%, 62.0%, 40.1%, and 66.7%, respectively. Univariate analysis revealed that lower LCR was significantly associated with shorter PFS (p = 0.0446).There was no significant difference between the median baseline values of PLR and NLR; and age ≥75, positive regional lymph node metastases (N+), and chemotherapy after RT were significantly associated with poor OS. Multivariate analysis revealed a significant association of N+ with worse OS, PFS, and CSS and that lower LCR was significantly associated with better PFS (p = 0.0234). Among late toxicity events, two patients (3.38%) were suspected with therapy-related liver toxicity.Conclusions: Lower LCR before RT was a better prognostic factor for postoperative RT of patients with CCA.

show abstract

Section: Discussionmentioning

confidence: 45%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic markers including immune and inflammatory factors predict outcomes in patients receiving postoperative radiation therapy for cholangiocarcinoma

Mukai

Matsuyama

Sugiura

et al. 2022

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

“…Comparisons with previous studies may be di cult because of their different populations and stages. Patients with an elevated NLR experience shorter survival [1,[33][34][35]. However, we show a signi cant association between LCR and PFS.…”

Section: Discussionmentioning

confidence: 51%

“…Most studies report that an elevated NLR before initial surgery, chemotherapy, or RT, or combined, is associated with poor prognoses of patients with lung cancer, uterine cervical cancer, ovarian cancer, and many other solid tumors [17,18,19,20]. In CCA, an elevated NLR immediately before surgery or chemotherapy potentially predicts shorter PFS and OS [1,[32][33][34][35]. In EHCC, the NLR is not signi cantly associated with PFS, CSS, or OS, although an elevated PLR is signi cantly associated with shorter PFS and OS [36].…”

Section: Discussionmentioning

confidence: 99%

Prognostic Makers Including Immune and Inflammatory Factors Predict Outcomes in Patients Receiving Postoperative Radiation Therapy for Cholangiocarcinoma

Mukai

Matsuyama

Sugiura

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose: This study aimed to analyze treatment outcomes and prognostic markers, including immune and inflammatory factors, of postoperative radiation therapy (RT) administered to patients with cholangiocarcinoma (CCA).Methods: We retrospectively selected 59 patients with CCA who underwent surgery and postoperative RT with curative intent from 2004 to 2019. Patients received external irradiation (50 Gy in 25 fractions) using three-dimensional RT. Overall survival (OS), cause-specific survival (CSS), progression-free survival (PFS), and locoregional control (LRC) rates of initial RT were assessed using the Kaplan–Meier method. Univariate and multivariate Cox proportional-hazards regression models were used to identify prognostic factors. We analyzed prognostic factors of inflammation, such as pre-RT platelet count, hemoglobin, lymphocyte count ratio (LCR) of the leukocyte count, platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR).Results: Tumor stages were distributed as follows: I (n = 8), II (n = 25), III (n = 15), and IVA (n = 11). The median follow-up was 24 months. Two-year OS, CSS, PFS, and LRC rates were 59.5%, 62.0%, 40.1%, and 66.7%, respectively. Univariate analysis revealed that lower LCR was significantly associated with shorter PFS (P = 0.0446, hazard ratio (HR): 1.90, 95%, confidence interval (CI): 1.02–3.58). There was no significant difference between the median baseline values of PLR and NLR; and age ≥75, positive regional lymph node metastases (N+), and chemotherapy after RT were significantly associated with poor OS. Multivariate analysis revealed a significant association of N+ with OS, PFS and CSS and that lower LCR was significantly associated with PFS (HR: 0.481, CI: 0.252–0.905, p=0.0234). Among late toxicity events, two patients (3.38%) were suspected with therapy-related liver toxicity.Conclusions: LCR before RT was a prognostic factor for postoperative radiation therapy of patients with CCA.

show abstract

Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers

Oğul

Kidi

Büyükşimşek

2020

J Gastrointest Canc

View full text Add to dashboard Cite

The Effect of Inflammatory Markers on Survival in Advanced Biliary Tract Carcinoma Treated with Gemcitabine/Oxaliplatin Regimen

Cited by 7 publications

References 34 publications

Prognostic markers including immune and inflammatory factors predict outcomes in patients receiving postoperative radiation therapy for cholangiocarcinoma

Prognostic markers including immune and inflammatory factors predict outcomes in patients receiving postoperative radiation therapy for cholangiocarcinoma

Prognostic Makers Including Immune and Inflammatory Factors Predict Outcomes in Patients Receiving Postoperative Radiation Therapy for Cholangiocarcinoma

Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers

Contact Info

Product

Resources

About